Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck m-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M)
Latest, Q2 2026
96
Period ended Jun 30, 2026
Change on a year earlier
+1.1%
95 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up m-m-r ii (measles, mumps and rubella virus vaccine) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_mmr_ii
See every metric in the Merck KPI table. Data updated Oct 26, 2026.